On Nov. 16, 2024, Professor of Pathology Beth Shaz, MD, MBA, published the fourth edition of her textbook, “Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects.” The book features short, concise chapters and has an easy-to-use format that serves as a quick reference for pathology and transfusion medicine for residents and fellows. It is also intended for physicians and allied health professionals who order and administer blood components, cellular therapies, specialized factors for hemostatic abnormalities, and coagulation testing.
Some of the new developments that have occurred since the previous edition are included, such as new blood products, new indications, or clinical conditions in which blood products are used. Similarly, this edition introduces new hemostasis testing, as well as new clinical scenarios due to the COVID-19 pandemic that are relevant to hemostasis and transfusion medicine.
Christopher D. Hillyer, MD, and Shaz have remained as primary editors since the book’s first publication in 2009. Other editors of this edition include Joseph “Yossi” Schwartz, MD, MPH, and Morayma Reyes Gil, MD.
“I am very grateful to all of the contributors helping to make the book possible,” said Shaz.
In addition to serving as chief of Clinical Pathology, Shaz is a professor of pathology and deputy director of the Marcus Center for Cellular Cures at Duke University. She’s a member of the Duke Cancer Institute and Margolis Institute for Health Policy, past president of the Association for the Advancement of Blood & Biotherapies (AABB) Board of Directors, and a scientific member of Biomedical Excellence for Safer Transfusion (BEST Collaborative).
She is an expert in transfusion medicine and cellular therapies, with over 20 years of experience. She is director of Duke’s Stem Cell Transplant Laboratory and associate director of the Carolinas Cord Blood Bank, one of the largest public cord blood banks in the world.
Shaz has published about 200 peer-reviewed articles and has co-edited 12 books. Her main goals are to improve the health of our community and ensure equal access to safe and efficacious blood and biotherapies.